Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Theralase Technologies Inc
(TSV:
TLT
)
0.1850
-0.0050 (-2.63%)
Streaming Delayed Price
Updated: 3:25 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,500
Open
0.1800
Bid (Size)
0.1750 (90)
Ask (Size)
0.1850 (1,950)
Prev. Close
0.1900
Today's Range
0.1800 - 0.1850
52wk Range
0.1400 - 0.2750
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via
ACCESSWIRE
Performance
YTD
N/A
N/A
1 Month
+8.82%
+8.82%
3 Month
+15.62%
+15.62%
6 Month
-7.50%
-7.50%
1 Year
-21.28%
-21.28%
More News
Read More
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via
ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Via
ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Via
ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Via
ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Via
ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Via
ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Via
ACCESSWIRE
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Via
ACCESSWIRE
Theralase(R) Expands Clinical Team
May 02, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via
ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via
ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via
ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via
ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via
ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via
ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via
ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.